A citation-based method for searching scientific literature

Naomi Alpert, Maaike van Gerwen, Emanuela Taioli. Transl Lung Cancer Res 2020
Times Cited: 39







List of co-cited articles
221 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia,[...]. Lancet 2021
276
30

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold,[...]. J Clin Oncol 2003
25

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
Michele Carbone, Prasad S Adusumilli, H Richard Alexander, Paul Baas, Fabrizio Bardelli, Angela Bononi, Raphael Bueno, Emanuela Felley-Bosco, Francoise Galateau-Salle, David Jablons,[...]. CA Cancer J Clin 2019
164
17

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Gérard Zalcman, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, Romain Corre, Isabelle Monnet, Valérie Gounant,[...]. Lancet 2016
521
17

Global Asbestos Disaster.
Sugio Furuya, Odgerel Chimed-Ochir, Ken Takahashi, Annette David, Jukka Takala. Int J Environ Res Public Health 2018
73
15

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Aliya Noor Husain, Thomas V Colby, Nelson G Ordóñez, Timothy Craig Allen, Richard Luther Attanoos, Mary Beth Beasley, Kelly Jo Butnor, Lucian R Chirieac, Andrew M Churg, Sanja Dacic,[...]. Arch Pathol Lab Med 2018
274
15

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).
Morihito Okada, Takashi Kijima, Keisuke Aoe, Terufumi Kato, Nobukazu Fujimoto, Kazuhiko Nakagawa, Yuichiro Takeda, Toyoaki Hida, Kuninobu Kanai, Fumio Imamura,[...]. Clin Cancer Res 2019
126
12

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
Raphael Bueno, Eric W Stawiski, Leonard D Goldstein, Steffen Durinck, Assunta De Rienzo, Zora Modrusan, Florian Gnad, Thong T Nguyen, Bijay S Jaiswal, Lucian R Chirieac,[...]. Nat Genet 2016
476
12

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Emilie van Brummelen. Lancet Oncol 2017
306
12

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Julija Hmeljak, Francisco Sanchez-Vega, Katherine A Hoadley, Juliann Shih, Chip Stewart, David Heiman, Patrick Tarpey, Ludmila Danilova, Esther Drill, Ewan A Gibb,[...]. Cancer Discov 2018
274
12

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
Hedy L Kindler, Nofisat Ismaila, Samuel G Armato, Raphael Bueno, Mary Hesdorffer, Thierry Jahan, Clyde Michael Jones, Markku Miettinen, Harvey Pass, Andreas Rimner,[...]. J Clin Oncol 2018
205
12

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez,[...]. Lancet Oncol 2019
236
12

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P Baas, D Fennell, K M Kerr, P E Van Schil, R L Haas, S Peters. Ann Oncol 2015
197
12

Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
Raffit Hassan, Betsy Morrow, Anish Thomas, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Meghana Gadiraju, Vasiliki Panou, Shaojian Gao, Idrees Mian,[...]. Proc Natl Acad Sci U S A 2019
72
10

A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.
Sandra Pastorino, Yoshie Yoshikawa, Harvey I Pass, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Tomoko Hashimoto-Tamaoki,[...]. J Clin Oncol 2018
70
10

High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.
Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, Masaki Ohmuraya, Ayuko Sato, Tohru Tsujimura, Seiki Hasegawa, Takashi Nakano, Masaki Nasu, Sandra Pastorino,[...]. Proc Natl Acad Sci U S A 2016
98
10

Mesothelioma epidemiology, carcinogenesis, and pathogenesis.
Haining Yang, Joseph R Testa, Michele Carbone. Curr Treat Options Oncol 2008
170
10

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Josine Quispel-Janssen, Vincent van der Noort, Jeltje F de Vries, Marion Zimmerman, Ferry Lalezari, Erik Thunnissen, Kim Monkhorst, Robert Schouten, Laurel Schunselaar, Maria Disselhorst,[...]. J Thorac Oncol 2018
142
10

Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.
Vanya Delgermaa, Ken Takahashi, Eun-Kee Park, Giang Vinh Le, Toshiyuki Hara, Tom Sorahan. Bull World Health Organ 2011
256
10

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Maria J Disselhorst, Josine Quispel-Janssen, Ferry Lalezari, Kim Monkhorst, Jeltje F de Vries, Vincent van der Noort, Emmy Harms, Sjaak Burgers, Paul Baas. Lancet Respir Med 2019
128
10

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, Chris Brown, Brett Gm Hughes, Deme J Karikios, Thomas John, Steven C-H Kao, Connull Leslie, Alistair M Cook,[...]. Lancet Oncol 2020
68
10

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Giorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, Takashi Nakano, Jan van Meerbeeck, Sanjay Popat, Nicholas J Vogelzang, Federica Grosso, Rasha Aboelhassan, Marko Jakopovic,[...]. Lancet Respir Med 2019
71
10

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim Aerts, Susana Cedres Perez, Alessandra Bearz, Kristiaan Nackaerts, Dean A Fennell, Dariusz Kowalski, Anne S Tsao,[...]. Lancet Oncol 2017
257
10

Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
Robert Ryan Meyerhoff, Chi-Fu Jeffrey Yang, Paul J Speicher, Brian C Gulack, Matthew G Hartwig, Thomas A D'Amico, David H Harpole, Mark F Berry. J Surg Res 2015
87
10

Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
Di Wu, Kenzo Hiroshima, Shinji Matsumoto, Kazuki Nabeshima, Toshikazu Yusa, Daisuke Ozaki, Michio Fujino, Hisami Yamakawa, Yukio Nakatani, Yuji Tada,[...]. Am J Clin Pathol 2013
71
10

MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
David B Chapel, Jefree J Schulte, Kyra Berg, Andrew Churg, Sanja Dacic, Carrie Fitzpatrick, Francoise Galateau-Salle, Kenzo Hiroshima, Thomas Krausz, Nolwenn Le Stang,[...]. Mod Pathol 2020
51
10

How asbestos and other fibers cause mesothelioma.
Giovanni Gaudino, Jiaming Xue, Haining Yang. Transl Lung Cancer Res 2020
23
13

Mesothelioma developing in carriers of inherited genetic mutations.
Yoshie Yoshikawa, Mitsuru Emi, Takashi Nakano, Giovanni Gaudino. Transl Lung Cancer Res 2020
14
21

Germline BAP1 mutations predispose to malignant mesothelioma.
Joseph R Testa, Mitchell Cheung, Jianming Pei, Jennifer E Below, Yinfei Tan, Eleonora Sementino, Nancy J Cox, A Umran Dogan, Harvey I Pass, Sandra Trusa,[...]. Nat Genet 2011
644
7

High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Masaki Nasu, Mitsuru Emi, Sandra Pastorino, Mika Tanji, Amy Powers, Hugh Luk, Francine Baumann, Yu-An Zhang, Adi Gazdar, Shreya Kanodia,[...]. J Thorac Oncol 2015
192
7

Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
Francine Baumann, Erin Flores, Andrea Napolitano, Shreya Kanodia, Emanuela Taioli, Harvey Pass, Haining Yang, Michele Carbone. Carcinogenesis 2015
143
7

BAP1 and cancer.
Michele Carbone, Haining Yang, Harvey I Pass, Thomas Krausz, Joseph R Testa, Giovanni Gaudino. Nat Rev Cancer 2013
397
7

Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey.
I Roushdy-Hammady, J Siegel, S Emri, J R Testa, M Carbone. Lancet 2001
165
7

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
Vasiliki Panou, Meghana Gadiraju, Arthur Wolin, Caroline M Weipert, Emily Skarda, Aliya N Husain, Jyoti D Patel, Buerkley Rose, Shannon R Zhang, Madison Weatherly,[...]. J Clin Oncol 2018
95
7

Malignant pleural mesothelioma: a population-based study of survival.
Michael T Milano, Hong Zhang. J Thorac Oncol 2010
100
7

The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure.
Alessandro Marinaccio, Marisa Corfiati, Alessandra Binazzi, Davide Di Marzio, Alberto Scarselli, Pierpaolo Ferrante, Michela Bonafede, Marina Verardo, Dario Mirabelli, Valerio Gennaro,[...]. Occup Environ Med 2018
39
7

Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.
Aaron S Mansfield, Tobias Peikert, James B Smadbeck, Julia B M Udell, Enrique Garcia-Rivera, Laura Elsbernd, Courtney L Erskine, Virginia P Van Keulen, Farhad Kosari, Stephen J Murphy,[...]. J Thorac Oncol 2019
63
7

Malignant Mesothelioma Mortality - United States, 1999-2015.
Jacek M Mazurek, Girija Syamlal, John M Wood, Scott A Hendricks, Ainsley Weston. MMWR Morb Mortal Wkly Rep 2017
79
7

Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.
Daniel R Gomez, David S Hong, Pamela K Allen, James S Welsh, Reza J Mehran, Anne S Tsao, Zhongxing Liao, Stephen D Bilton, Ritsuko Komaki, David C Rice. J Thorac Oncol 2013
81
7

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
Andreas Rimner, Marjorie G Zauderer, Daniel R Gomez, Prasad S Adusumilli, Preeti K Parhar, Abraham J Wu, Kaitlin M Woo, Ronglai Shen, Michelle S Ginsberg, Ellen D Yorke,[...]. J Clin Oncol 2016
102
7

Malignant pleural mesothelioma.
Anne S Tsao, Ignacio Wistuba, Jack A Roth, Hedy Lee Kindler. J Clin Oncol 2009
236
7

The MARS feasibility trial: conclusions not supported by data.
Walter Weder, Rolf A Stahel, Paul Baas, Urania Dafni, Marc de Perrot, Brian C McCaughan, Takashi Nakano, Harvey I Pass, Bruce W S Robinson, Valerie W Rusch,[...]. Lancet Oncol 2011
86
7

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
Nico van Zandwijk, Christopher Clarke, Douglas Henderson, A William Musk, Kwun Fong, Anna Nowak, Robert Loneragan, Brian McCaughan, Michael Boyer, Malcolm Feigen,[...]. J Thorac Dis 2013
140
7

Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.
Amelia O Clive, Hazel Taylor, Lee Dobson, Paula Wilson, Emma de Winton, Niki Panakis, Justin Pepperell, Timothy Howell, Samuel A Stewart, Erika Penz,[...]. Lancet Oncol 2016
82
7

Novel therapies for malignant pleural mesothelioma.
Arnaud Scherpereel, Frederic Wallyn, Steven M Albelda, Camille Munck. Lancet Oncol 2018
88
7

Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology.
Anders Hjerpe, Valeria Ascoli, Carlos W M Bedrossian, Mathilde E Boon, Jenette Creaney, Ben Davidson, Annika Dejmek, Katalin Dobra, Ambrogio Fassina, Andrew Field,[...]. Acta Cytol 2015
48
7


Malignant mesothelioma.
Bruce W S Robinson, Arthur W Musk, Richard A Lake. Lancet 2005
547
7

Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
David B Chapel, Jefree J Schulte, Aliya N Husain, Thomas Krausz. Transl Lung Cancer Res 2020
34
8

Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.
Neil Bayman, Wiebke Appel, Linda Ashcroft, David R Baldwin, Andrew Bates, Liz Darlison, John G Edwards, Veni Ezhil, David Gilligan, Matthew Hatton,[...]. J Clin Oncol 2019
27
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.